A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Phase of Trial: Phase I/II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Pacritinib (Primary) ; Sirolimus; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 22 Jan 2018 Planned End Date changed from 31 Jan 2019 to 31 Jan 2020.
- 10 Jun 2017 Biomarkers information updated
- 30 Mar 2017 Status changed from not yet recruiting to recruiting.